Expertise in
11
conditions

Dr. Yanis A. Boumber

University Of Alabama Health Services Foundation, PC
Birmingham, AL
Expertise in
11
conditions
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Offers Telehealth
Expertise in
11
conditions
OverviewInsuranceLocationsClinical Research

Overview

Yanis Boumber is a Hematologist Oncology specialist and an Oncologist in Birmingham, Alabama. Dr. Boumber is highly rated in 11 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Boumber is currently accepting new patients.

His clinical research consists of co-authoring 49 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in AL
Hospital Affiliations
Northwestern Memorial Hospital
University Of Alabama Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION, PC
619 19th St S, Birmingham, AL 35246
205-934-3460

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: January 03, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug, Biological
Study Drugs: Ficlatuzumab, Cetuximab
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 02, 2024
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas
Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas
Enrollment Status: Completed
Publish Date: July 22, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Enrollment Status: Completed
Publish Date: October 08, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

49 Total Publications

A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 08, 2024
Similar Doctors
Expertise in
36
conditions
Dr. Amitkumar N. Mehta
Hematology Oncology | Hematology | Oncology
Expertise in
36
conditions
Dr. Amitkumar N. Mehta
Hematology Oncology | Hematology | Oncology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (1.0 mi)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amitkumar Mehta is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Mehta is highly rated in 36 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Tissue Biopsy. Dr. Mehta is currently accepting new patients.

Expertise in
19
conditions
Dr. Gaurav N. Goyal
Hematology Oncology | Hematology | Oncology
Expertise in
19
conditions
Dr. Gaurav N. Goyal
Hematology Oncology | Hematology | Oncology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (1.0 mi)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gaurav Goyal is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Goyal is highly rated in 19 conditions, according to our data. His top areas of expertise are Reticulohistiocytoma, Histiocytosis, Langerhans Cell Histiocytosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Goyal is currently accepting new patients.

Andres Forero-Torres
Expertise in
26
conditions
Dr. Andres Forero-Torres
Hematology Oncology | Hematology | Oncology
Expertise in
26
conditions
Dr. Andres Forero-Torres
Hematology Oncology | Hematology | Oncology
619 19th St S, 
Birmingham, AL 
 (1.0 mi)
205-934-6600
Languages Spoken:
English

Andres Forero-Torres is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Forero-Torres is highly rated in 26 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, HER-2 Positive Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, and Bone Marrow Aspiration.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile